Resources

Getting PrEP Rollout Right This Time

Getting PrEP Rollout Right This Time: Lessons from the Field examines key insights from the rollout of oral PrEP and early introduction of injectable CAB and the dapivirine vaginal ring to inform a faster, smarter and more equitable introduction of future HIV prevention tools, including long-acting injectable PrEP, such as lenacapavir.

The Scientific Journey of Lenacapavir — and the Urgency to Defend HIV Prevention Science 

On June 11, AVAC hosted a conversation, The Scientific Journey of Lenacapavir: From basic science to clinical development to impact, to explore how US support from NIH for basic science and South Africa’s clinical research infrastructure made possible the development of lenacapavir for PrEP (LEN), a discovery in HIV prevention that went on to be named Science magazine’s 2024 Breakthrough of the Year.

As the field anticipates initial regulatory approval from the US FDA by June 19 and a WHO recommendation in July, Linda-Gail Bekker of the Desmond Tutu Health Foundation, Wes Sundquist of the University of Utah and Mitchell Warren of AVAC underscored how this moment of promise is threatened by sweeping attacks on science, research and the very systems that made the development of LEN possible.

HIV Prevention R&D at Risk

AVAC’s analysis of the impact of US Government funding cuts, terminated projects, and other policy changes on the HIV prevention research and development (R&D) pipeline, and on HIV research broadly.

Protect Federal Funding for HIV, TB, and STI Research and Prevention at the National Institutes of Health

AVAC and 627 organizations, institutions, researchers, clinicians, public health advocates and stakeholders submitted a written letter to the Senate HELP Committee urging lawmakers to reject the cuts to NIH funding for HIV, TB, and STI research and highlighting the impact of these cuts on lifesaving innovation and research infrastructure.

Why HIV Prevention Must Not Be Left Behind

In this presentation at the INTEREST 2025 conference, Rhoda Msiska of Copper Rose Zambia emphasizes the urgency of protecting the progress made in scaling up PrEP and the need to act now to expand access to new HIV prevention tools like injectable lenacapavir (LEN) and the Dual Prevention Pill (DPP).

Advocates’ Guide: Understanding the President’s Proposed Fiscal Year 2026 (FY26) Budget and Its Implications for Science, Research and Global Health 

The US administration’s proposed Fiscal Year 2026 (FY26) budget marks a sweeping rollback of federal investment in health, research, and global development. For advocates, researchers, and implementers, this proposal demands urgent attention and action.

Worldwide Prevention, Shared Protection

This Issue Brief describes the impacts of the elimination and reduction of funding that supports sexually transmitted infection (STI) research, testing, and prevention programming. This funding is critically important as STI rates continue to increase globally with more than 1 million curable STIs, including chlamydia, gonorrhea, syphilis, and trichomoniasis, acquired every day. Without appropriate testing, treatment, and prevention programs, there is a risk that STI rates will continue to increase leading to more cases of infertility, pelvic inflammatory disease, and cancers.

Critical Advocacy: How Civil Society is defending the HIV Response and Global Health 

In this episode of PxPulse Live, two veteran global health leaders from civil society join us to talk about how civil society is responding. Amanda Banda is Strategic Advisor to the COMPASS Coalition and Asia Russell is Executive Director of Health Gap, and both are members of CHANGE, a coalition with more than 1,500 people, from organizations in nearly every continent, working in coordination to defend global health and the HIV response.

PxWire Volume 15, Issue 2

The field of HIV prevention is confronted with two opposing forces—programs for delivering PrEP have been shuttered all over the world by the withdrawal of the US government from global health while next-generation long-acting products have never held greater promise to accelerate HIV prevention and help the world achieve epidemic control. This issue provides a snapshot on threats to delivering PrEP, the potential of injectable lenacapavir (LEN) for PrEP, and on the implications of upstream research and development of other long-acting PrEP.

PrEP Delivery Imperiled

Programs for delivering PrEP have been shuttered all over the world by the withdrawal of the US government from global health. This graphic illustrates some of the severe measurable impacts of these cuts.